As part of Macula Month this May, Insight examines drug development programs that could significantly alter the late-stage AMD therapy...
Read moreDetailsAustralia’s first clinical trials of an investigational gene therapy for dry age-related macular degeneration (AMD) has commenced at the Centre...
Read moreDetailsAn independent expert panel has recommended Novartis' treatment Beovu be subsidised through the Pharmaceutical Benefits Scheme (PBS) for neovascular age-related...
Read moreDetailsTwo years since the KeepSight launch, Insight asks what measurable difference this once-in-a-generation program is making to those living with...
Read moreDetailsA new diabetic eye clinic for children in Western Australia, which opened last month, is part of the Lions Eye Institute's first major...
Read moreDetailsNova Eye Medical has announced positive five-year follow-up data from a sub-study analysis of the multi-centre LEAD trial for its...
Read moreDetailsThe Australian government spent more than $610 million on anti-VEGF treatments during the past year, with aflibercept (Eylea) leapfrogging a...
Read moreDetailsA clinical trial is under way in Australia for a novel eye drop treatment for retinal vascular diseases that could...
Read moreDetailsResearchers from the Centre for Eye Research Australia and University of Melbourne have developed a world-first survey to gather the...
Read moreDetailsAn Australian researcher has contributed to a new study demonstrating that lower carbohydrate consumption can potentially put type 2 diabetes...
Read moreDetails
Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.
© 2026 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited
© 2026 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited